Bisolvon inj

As part of combination therapy for acute and chronic bronchopulmonary diseases, accompanied by the formation of a difficult-to-separate viscous secretion:

bronchial asthma,

tracheobronchitis,

obstructive bronchitis,

pneumonia,

emphysema of the lungs,

whooping cough,

pneumoconiosis,

tuberculosis of the lungs.

Inside, 3 times a day. Adults and children over 12 years — 1 table., children from 6 to 12 years-1/2 or 1 table.

Children under the age of 6 years are recommended to use Ascoril expectorant syrup.

hypersensitivity to the components of the drug,

tachyarrhythmia, myocarditis,

heart defects,

decompensated diabetes mellitus,

thyrotoxicosis,

glaucoma,

liver or kidney failure,

peptic ulcer of the stomach and duodenum in the acute stage,

gastric bleeding,

arterial hypertension,

pregnancy,

lactation period,

children under 6 years of age.

With caution it is prescribed to patients with diabetes mellitus, gastric ulcer and duodenal ulcer in remission.

Bisolvon inj is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.

A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.

Bisolvon inj hydrochloride SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.

The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.

According to WHO, adverse effects are classified according to their frequency of development as follows: very common (≥1/10), common (≥1/100 to <1/10), infrequent (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000), frequency unknown — according to available data, it was not possible to determine the frequency of occurrence.

From the immune system: rarely-hypersensitivity reactions, frequency unknown-anaphylactic reactions, including anaphylactic shock, angioedema and pruritus.

From the central nervous system: rarely-headache, dizziness, increased nervous excitability, sleep disturbance, drowsiness, tremor, convulsions.

From the CCC side: rarely-rapid heartbeat, collapse.

From the respiratory system, chest and mediastinal organs: rarely-bronchospasm.

From the gastrointestinal tract: rarely — nausea, vomiting, diarrhea, exacerbation of gastric ulcer and duodenal ulcer.

From the kidneys and urinary system: rarely-it is possible to stain the urine in pink.

From the skin and subcutaneous tissues: rarely-rash, urticaria, frequency unknown-severe skin adverse reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis associated with the use of ambroxol (ambroxol is a metabolite of bromhexine).

Symptoms: increased manifestations of side effects.

Treatment: symptomatic therapy.

Bromhexine, Guaifenesin, Racementhol, Salbutamol